$ATOS Just for context AstraZeneca paid Daiichi $6 Billion with $1 Billion upfront payment. When they announced the deal - it was Phase 1 approved. nature.com/articles/d43747-... Here are the sales forecast for the drug - $1.2x billion by 2026. There's competition from Gilead. They need Endoxifen to just capture the entire market!
2
23
23 Likes